Takeda Pharmaceutical Company Limited (TKPHF)

Market Cap	59.74B +46.1%
Revenue (ttm)	28.48B -2.5%
Net Income	720.25M -45.7%
EPS	0.45 -45.9%
Shares Out	n/a
PE Ratio	82.94
Forward PE	n/a
Dividend	1.32 (3.50%)
Ex-Dividend Date	Mar 30, 2026

Volume	300
Average Volume	90,948
Open	37.80
Previous Close	39.20
Day's Range	37.80 - 37.80
52-Week Range	26.10 - 39.20
Beta	0.08
RSI	65.15
Earnings Date	Jan 29, 2026

About TKPHF

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1781
• Employees: 47,455
• Stock Exchange: OTCMKTS
• Ticker Symbol: TKPHF

Financial Performance

In fiscal year 2025, TKPHF's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY